Licensing & Dealmaking Case Studies: Negotiation Support

Case Study 1, Challenge: A publicly-traded mid-cap biotech was negotiating a term sheet with a potential licensor and asked Alacrita for input into critical financial terms. The asset was a cell...
Learn More

Due diligence: biologic technologies & phase III probability of success of CNS asset

Case Study 1, Challenge: A mid-size pharmaceutical company seeking opportunities to diversify within its core therapeutic area by partnering in products based on biologic technologies retained...
Learn More

Due diligence: plasma protein manufacturer; Phase III gene therapy asset

Case Study 1, Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in...
Learn More

Developing an independent market report for a cannabinoid company seeking a dual-listing

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...
Learn More

Roadmap for commercial data infrastructure build to support rare disease drug launch

Challenge: Our client was a clinical-stage biotech in the process of early stage planning for the launch of its first drug, a small molecule treatment for a rare endocrine disorder. However, the...
Learn More

University life sciences IP and project portfolio review

Challenge: Alacrita developed techno-commercial development plans for selected top priority projects. The client, King's Commercialisation Institute, convened an expert panel which then selected...
Learn More

Commercial development plan for a mesenchymal stem cell therapy in acute GvHD

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the university. Alacrita was...
Learn More

Cell and gene therapy manufacturing facility planning

Challenge A new GMP facility for the production of investigational cell and gene therapies needed regulatory, market and technical advice before committing to a capacity expansion.
Learn More

Due diligence on a new medical imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Providing expert due diligence for the reformulation of a marketed biologic

Challenge An established European pharma company needed an opportunity assessment for a reformulation of a marketed biologic.
Learn More

Opportunity map for 3D Printing Technology for medical products

Challenge: A university commercialization institute asked Alacrita to review its technology for 3D printed, customised silicone medical products. The main task was to determine the prospective value...
Learn More

Medical oversight support for oncology clinical trials

Challenge:  A listed biotech company conducting Phase III clinical trials in an oncology indication needed Chief Medical Officer support for multiple clinical activities in Europe and the United...
Learn More
1 2 3 4 5 ... 19
Next

Facing a complex life science challenge? We can help.

Contact us today to learn how our consulting expertise can serve your project.

Contact us

Explore our life science consulting services

© 2019 Alacrita Holdings Limited   |  Life Science Consulting

Alacrita Consulting Ltd
2 Royal College St,
London,
NW1 0NH

Registered in England & Wales.
No. 10530608


303 Wyman Street,
Waltham,
MA 02451

Registered in Massachusetts.


Artherstrasse 7,
6300 Zug,
Switzerland

Registered in Switzerland.
No. CHE-233.138.008